PharmacoEconomics

1997 - 2025

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 40, issue 12, 2022

Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries pp. 1131-1142

Leah Z. Rand and Aaron S. Kesselheim

Economic Implications of Endometriosis: A Review pp. 1143-1158

Josep Darbà and Alicia Marsà

A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia pp. 1159-1186

Rumjhum Agrawal, Joao Vieira, Jacqueline Ryan, Harish Negi, Tanvi Rajput, Regina Corbin and Ricardo Viana

Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting pp. 1187-1205

Xinyue Dong, Xiaoning He and Jing Wu

Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial pp. 1207-1220

Edna Keeney, Sabina Sanghera, Richard M. Martin, Roman Gulati, Fredrik Wiklund, Eleanor I. Walsh, Jenny L. Donovan, Freddie Hamdy, David E. Neal, J. Athene Lane, Emma L. Turner, Howard Thom and Mark S. Clements

Conceptual Framework for Optimised Proxy Value Set Selection Through Supra-National Value Set Development for the EQ-5D Instruments pp. 1221-1234

Agata Łaszewska, Ayesha Sajjad, Jan Busschbach, Judit Simon and Leona Hakkaart- van Roijen

Efficiency of the EmERGE Pathway of Care in Five European HIV Centres pp. 1235-1246

Eduard J. Beck, Sundhiya Mandalia, Platon Yfantopoulos, Agathe Leon, Marie J. Merino, Felipe Garcia, Marie Wittevogel, Ludwig Apers, Ivana Benkovic, Sime Zekan, Josip Begovac, Ana S. Cunha, Eugenio Teofilo, Goncalo Rodrigues, Margarida D. F. Borges, Duncan Fatz, Jamie Vera and Jennifer Whetham

Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer’s Perspective pp. 1247-1259

Tingting Qu, Shujing Zhang, Yichen Zhong, Yang Meng, He Guo, Seongjung Joo and Peter C. Enzinger

Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia” pp. 1261-1263

Bhaskar Rege, James McGrory, Sabina Gasper and David McDonnell

Response to Comment on “An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia” pp. 1265-1267

Marjanne A. Piena, Natalie Houwing, Carla W. Kraan, Xiaofeng Wang, Heidi Waters and Craig Bennison

Volume 40, issue 11, 2022

A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process pp. 1015-1032

Fang Li, Frederike Jörg, Xinyu Li and Talitha Feenstra

Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian Randomisation pp. 1033-1042

Zanfina Ademi, Jedidiah I. Morton, Danny Liew, Stephen J. Nicholls, Sophia Zoungas and Brian A. Ference

Are We Agreed? Self- Versus Proxy-Reporting of Paediatric Health-Related Quality of Life (HRQoL) Using Generic Preference-Based Measures: A Systematic Review and Meta-Analysis pp. 1043-1067

Diana Khanna, Jyoti Khadka, Christine Mpundu-Kaambwa, Kiri Lay, Remo Russo and Julie Ratcliffe

Valuing the Quality-of-Life Aged Care Consumers (QOL-ACC) Instrument for Quality Assessment and Economic Evaluation pp. 1069-1079

Julie Ratcliffe, Siobhan Bourke, Jinhu Li, Brendan Mulhern, Claire Hutchinson, Jyoti Khadka, Rachel Milte and Emily Lancsar

Is EQ-5D-5L Better Than EQ-5D-3L Over Time? A Head-to-Head Comparison of Responsiveness of Descriptive Systems and Value Sets from Nine Countries pp. 1081-1093

Mathieu F. Janssen, Ines Buchholz, Dominik Golicki and Gouke J. Bonsel

A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates pp. 1095-1105

Gian Luca Di Tanna, Blake Angell, Michael Urbich, Peter Lindgren, Thomas A. Gaziano, Gary Globe and Björn Stollenwerk

The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA pp. 1107-1117

Ali Tafazzoli, Scott D. Ramsey, Alissa Shaul, Ameya Chavan, Weicheng Ye, Anuraag R. Kansal, Josh Ofman and A. Mark Fendrick

Engaging Patients and Caregivers in an Early Health Economic Evaluation: Discerning Treatment Value Based on Lived Experience pp. 1119-1130

Mackenzie Wilson, Kednapa Thavorn, Terry Hawrysh, Ian D. Graham, Harold Atkins, Natasha Kekre, Doug Coyle, Manoj M. Lalu, Dean A. Fergusson, Kelvin K. W. Chan, Daniel A. Ollendorf and Justin Presseau

Volume 40, issue 10, 2022

Tools for the Economic Evaluation of Precision Medicine: A Scoping Review of Frameworks for Valuing Heterogeneity-Informed Decisions pp. 931-941

Reka E. Pataky, Stirling Bryan, Mohsen Sadatsafavi, Stuart Peacock and Dean A. Regier

Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review pp. 943-956

Suzana Karim, Benjamin M. Craig, Caroline Vass and Catharina G. M. Groothuis-Oudshoorn

China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population pp. 957-969

Jing Wu, Xiaoning He, Pinan Chen, Shitong Xie, Xue Li, Hao Hu, Kun Zhao and Feng Xie

Collaborating with Patient Partners to Model Clinical Care Pathways in Major Depressive Disorder: The Benefits of Mixing Evidence and Lived Experience pp. 971-977

Mary Bunka, Shahzad Ghanbarian, Linda Riches, Ginny Landry, Louisa Edwards, Alison M. Hoens and Stirling Bryan

Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA pp. 979-988

Jing Voon Chen, James C. Gahn, Jeffrey Nesheim and Paul N. Mudd,

A Comparison of the Content and Consistency of Methodological Quality and Transferability Checklists for Reviewing Model-Based Economic Evaluations pp. 989-1003

Ka Keat Lim, Rositsa Koleva-Kolarova and Julia Fox-Rushby

Developing an Online Infrastructure to Enhance Model Accessibility and Validation: The Peer Models Network pp. 1005-1009

Stephanie Harvard, Amin Adibi, Adam Easterbrook, Gregory R. Werker, David Murphy, Don Grant, Alison Mclean, Zhina Majdzadeh and Mohsen Sadatsafavi

Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine” pp. 1011-1012

Nikolaos Giannelos, Marie Libérée Nishimwe and Nicolas Lecrenier

Authors’ Reply to Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison Between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine” pp. 1013-1014

Joke Bilcke and Philippe Beutels

Volume 40, issue 9, 2022

Carers’ Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations pp. 837-850

Becky Pennington, Jack Eaton, Anthony J Hatswell and Helen Taylor

Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 851-861

Thomas Otten, Rob Riemsma, Ben Wijnen, Nigel Armstrong, Lisa Stirk, Caroline Gordon, Bram Ramaekers, Jos Kleijnen, Manuela Joore and Sabine Grimm

A Systematic Review of the Methodologies and Modelling Approaches Used to Generate International EQ-5D-5L Value Sets pp. 863-882

Donna Rowen, Clara Mukuria and Emily McDool

Best–Worst Scaling and the Prioritization of Objects in Health: A Systematic Review pp. 883-899

Ilene L. Hollin, Jonathan Paskett, Anne L. R. Schuster, Norah L. Crossnohere and John F. P. Bridges

Does the Structure Matter? An External Validation and Health Economic Results Comparison of Event Simulation Approaches in Severe Obesity pp. 901-915

Björn Schwander, Klaus Kaier, Mickaël Hiligsmann, Silvia Evers and Mark Nuijten

The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada pp. 917-928

Christopher Hillis, Colin Vicente and Graeme Ball

Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective” pp. 929-930

Afschin Gandjour

Volume 40, issue 8, 2022

A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 Diabetes pp. 743-750

Ágnes Benedict, Emily R. Hankosky, Kinga Marczell, Jieling Chen, David J. Klein, J. Jaime Caro, Jay P. Bae and Brian D. Benneyworth

The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review pp. 751-776

Michal Witkowski, Søren Ilsøe Moreno, João Fernandes, Pierre Johansen, Margarida Augusto and Sunita Nair

Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective pp. 777-790

Keith W. Pratz, Xinglei Chai, Jipan Xie, Lei Yin, Xiaoyu Nie, Melissa Montez, Erica Iantuono, Lisa Downs and Esprit Ma

Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease pp. 791-806

Katya Galactionova, Paola Salari, Renato Mattli, Yael Rachamin, Rahel Meier and Matthias Schwenkglenks

Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia pp. 807-821

Rachel Song, Varinder Jeet, Rajan Sharma, Martin Hoyle and Bonny Parkinson

The Opportunity of Point-of-Care Diagnostics in General Practice: Modelling the Effects on Antimicrobial Resistance pp. 823-833

Simon Pol, Danielle E. M. C. Jansen, Alike W. Velden, Christopher C. Butler, Theo J. M. Verheij, Alex W. Friedrich, Maarten J. Postma and Antoinette D. I. Asselt

Correction to: Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease pp. 835-835

Katya Galactionova, Paola Salari, Renato Mattli, Yael Rachamin, Rahel Meier and Matthias Schwenkglenks

Volume 40, issue 7, 2022

Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers pp. 647-652

Jakub Hlavka, Tara A. Lavelle, Peter J. Neumann and Pei-Jung Lin

Considerations Around Coding the Membership Probability Function in a Latent Class Analysis: Renewed Insights pp. 653-661

Marco Boeri, Brett Hauber and Joseph C. Cappelleri

Preference Elicitation Techniques Used in Valuing Children’s Health-Related Quality-of-Life: A Systematic Review pp. 663-698

Cate Bailey, Martin Howell, Rakhee Raghunandan, Amber Salisbury, Gang Chen, Joanna Coast, Jonathan C. Craig, Nancy Devlin, Elisabeth Huynh, Emily Lancsar, Brendan J. Mulhern, Richard Norman, Stavros Petrou, Julie Ratcliffe, Deborah J. Street, Kirsten Howard and Rosalie Viney

Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US pp. 699-714

Hardik Goswami, Adnan Alsumali, Yiling Jiang, Matthias Schindler, Elizabeth R. Duke, Joshua Cohen, Andrew Briggs and Amy Puenpatom

Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China pp. 715-724

Yichen Zhang, Yuxuan Wei, Huangqianyu Li, Yixuan Chen, Yiran Guo, Sheng Han, Luwen Shi and Xiaodong Guan

Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study pp. 725-737

Shuxia Qin, Xuehong Wang, Sini Li, Chongqing Tan, Xiaohui Zeng, Xia Luo, Lidan Yi, Liubao Peng, Meiyu Wu, Ye Peng, Liting Wang and Xiaomin Wan

Risk-Adjusted Performance Measures: A Comment on Elbasha pp. 739-740

Pedram Sendi and Matthias Schwenkglenks

Authors’ Reply to Comment on “Risk-Adjusted Performance Measures” pp. 741-742

Elamin H. Elbasha

Volume 40, issue 6, 2022

Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges pp. 577-586

Manuel Gomes, Nick Latimer, Marta Soares, Sofia Dias, Gianluca Baio, Nick Freemantle, Dalia Dawoud, Allan Wailoo and Richard Grieve

Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability pp. 587-599

Zsombor Zrubka, Márta Péntek, Lea Mhanna, Teebah Abu-Zahra, Mohamed Mahdi-Abid, Meriem Fgaier, Faris El-Dahiyat, Hana Al-Abdulkarim, Michael Drummond and László Gulácsi

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations pp. 601-609

Don Husereau, Michael Drummond, Federico Augustovski, Esther Bekker-Grob, Andrew H. Briggs, Chris Carswell, Lisa Caulley, Nathorn Chaiyakunapruk, Dan Greenberg, Elizabeth Loder, Josephine Mauskopf, C. Daniel Mullins, Stavros Petrou, Raoh-Fang Pwu and Sophie Staniszewska

A Comparison of Methods for Identifying Informal Carers: Self-Declaration Versus a Time Diary pp. 611-621

Sean Urwin, Yiu-Shing Lau, Gunn Grande and Matt Sutton

Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer pp. 623-631

Woojung Lee, William B. Wong, Stacey Kowal, Louis P. Garrison, David L. Veenstra and Meng Li

Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups pp. 633-645

Ellen Rafferty, Mike Paulden, Sarah A. Buchan, Joan L. Robinson, Julie A. Bettinger, Manoj Kumar, Lawrence W. Svenson and Shannon E. MacDonald

Volume 40, issue 5, 2022

Exploring the Issues of Valuing Child and Adolescent Health States Using a Mixed Sample of Adolescents and Adults pp. 479-488

Donna Rowen, Clara Mukuria, Philip A. Powell and Allan Wailoo

Assessments of the Value of New Interventions Should Include Health Equity Impact pp. 489-495

Jeroen P. Jansen, Thomas A. Trikalinos and Kathryn A. Phillips

Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches pp. 497-507

Elamin H. Elbasha

Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 509-518

Sabine E. Grimm, Willem Witlox, Robert Wolff, Annette Chalker, Mickael Hiligsmann, Ben Wijnen, Charlotte Ahmadu, Steve Ryder, Nigel Armstrong, Steven Duffy, Isabel Syndikus, Jos Kleijnen and Manuela A. Joore

Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review pp. 519-558

Min Huang, Amin Haiderali, Grace E. Fox, Andrew Frederickson, Javier Cortes, Peter A. Fasching and Joyce O’Shaughnessy

The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England pp. 559-574

K. Ray Chaudhuri, A. Simon Pickard, Ali Alobaidi, Yash J. Jalundhwala, Prasanna L. Kandukuri, Yanjun Bao, Julia Sus, Glynn Jones, Christian Ridley, Julia Oddsdottir, Seyavash Najle-Rahim, Matthew Madin-Warburton, Weiwei Xu and Anette Schrag

Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 575-575

Sabine E. Grimm, Willem Witlox, Robert Wolff, Annette Chalker, Mickael Hiligsmann, Ben Wijnen, Charlotte Ahmadu, Steve Ryder, Nigel Armstrong, Steven Duffy, Isabel Syndikus, Jos Kleijnen and Manuela A. Joore

Volume 40, issue 4, 2022

Calibrating Natural History of Cancer Models in the Presence of Data Incompatibility: Problems and Solutions pp. 359-366

Olena Mandrik, Chloe Thomas, Sophie Whyte and James Chilcott

Economic Evaluation of Digital Health Interventions: Methodological Issues and Recommendations for Practice pp. 367-378

Manuel Gomes, Elizabeth Murray and James Raftery

Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures pp. 379-431

Joseph Kwon, Louise Freijser, Elisabeth Huynh, Martin Howell, Gang Chen, Kamran Khan, Shahd Daher, Nia Roberts, Conrad Harrison, Sarah Smith, Nancy Devlin, Kirsten Howard, Emily Lancsar, Cate Bailey, Jonathan Craig, Kim Dalziel, Alison Hayes, Brendan Mulhern, Germaine Wong, Julie Ratcliffe and Stavros Petrou

The EQ-5D-5L Valuation Study in Egypt pp. 433-447

Sahar Al Shabasy, Maggie Abbassi, Aureliano Finch, Bram Roudijk, Darrin Baines and Samar Farid

Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia pp. 449-460

Kaitlyn Hastings, Clara Marquina, Jedidiah Morton, Dina Abushanab, Danielle Berkovic, Stella Talic, Ella Zomer, Danny Liew and Zanfina Ademi

Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine pp. 461-476

Zoë Pieters, Benson Ogunjimi, Philippe Beutels and Joke Bilcke

Correction to: Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures pp. 477-478

Joseph Kwon, Louise Freijser, Elisabeth Huynh, Martin Howell, Gang Chen, Kamran Khan, Shahd Daher, Nia Roberts, Conrad Harrison, Sarah Smith, Nancy Devlin, Kirsten Howard, Emily Lancsar, Cate Bailey, Jonathan Craig, Kim Dalziel, Alison Hayes, Brendan Mulhern, Germaine Wong, Julie Ratcliffe and Stavros Petrou

Volume 40, issue 3, 2022

Four Aspects Affecting Health Economic Decision Models and Their Validation pp. 241-248

Talitha Feenstra, Isaac Corro-Ramos, Dominique Hamerlijnck, George Voorn and Salah Ghabri

Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time pp. 249-256

Gemma E. Shields, Becky Pennington, Ash Bullement, Stuart Wright and Jamie Elvidge

Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models pp. 257-268

Min Huang, Scott Ramsey, Weiguang Xue, Jipan Xie, James Pellissier and Andrew Briggs

Deprescribing Interventions among Community-Dwelling Older Adults: A Systematic Review of Economic Evaluations pp. 269-295

Sónia Romano, Débora Figueira, Inês Teixeira and Julian Perelman

A Comparison of PROPr and EQ-5D-5L Value Sets pp. 297-307

Tianxin Pan, Brendan Mulhern, Rosalie Viney, Richard Norman, Janel Hanmer and Nancy Devlin

Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol pp. 309-321

Fan Yang, Kenneth R. Katumba, Bram Roudijk, Zhihao Yang, Paul Revill, Susan Griffin, Perez N. Ochanda, Mohammed Lamorde, Giulia Greco, Janet Seeley and Mark Sculpher

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom pp. 323-339

Timothy Spelman, William L. Herring, Yuanhui Zhang, Michael Tempest, Isobel Pearson, Ulrich Freudensprung, Carlos Acosta, Thibaut Dort, Robert Hyde, Eva Havrdova, Dana Horakova, Maria Trojano, Giovanna Luca, Alessandra Lugaresi, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Raed Alroughani, Eugenio Pucci, Franco Granella, Jeannette Lechner-Scott, Patrizia Sola, Diana Ferraro, Francois Grand’Maison, Murat Terzi, Csilla Rozsa, Cavit Boz, Raymond Hupperts, Vincent Pesch, Celia Oreja-Guevara, Anneke Walt, Vilija G. Jokubaitis, Tomas Kalincik and Helmut Butzkueven

Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment pp. 341-354

Gabin F. Morillon and Thomas G. Poder

Correction to: Contextual Considerations and Recommendations for Estimating the Value of Alzheimer’s Disease Therapies pp. 355-355

T. Joseph Mattingly, R. Brett McQueen and Pei-Jung Lin

Correction to: Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment pp. 357-357

Gabin F. Morillon and Thomas G. Poder

Volume 40, issue 2, 2022

EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions pp. 123-127

Nancy Devlin, Bram Roudijk, Rosalie Viney and Elly Stolk

Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L pp. 129-137

David J. Mott, Nancy J. Devlin, Simone Kreimeier, Richard Norman, Koonal K. Shah and Oliver Rivero-Arias

Findings from a Roundtable Discussion with US Stakeholders on Valuation of the EQ-5D-Y-3L pp. 139-146

Jonathan L. Nazari, A. Simon Pickard and Ning Yan Gu

Future Offspring Costs in Economic Evaluation pp. 141-147

Evelyn Verbeke and Jeroen Luyten

Estimating an EQ-5D-Y-3L Value Set for China pp. 147-155

Zhihao Yang, Jie Jiang, Pei Wang, Xuejing Jin, Jing Wu, Yu Fang, Da Feng, Xiaoyu Xi, Shunping Li, Mingxia Jing, Bin Zheng, Weidong Huang and Nan Luo

Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency pp. 149-156

Gemma E. Shields, Mark Wilberforce, Paul Clarkson, Tracey Farragher, Arpana Verma and Linda M. Davies

How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents pp. 157-182

Cate Bailey, Kim Dalziel, Paula Cronin, Nancy Devlin and Rosalie Viney

Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values pp. 157-167

Titi Sahidah Fitriana, Bram Roudijk, Fredrick Dermawan Purba, Jan J. V. Busschbach and Elly Stolk

An EQ-5D-Y-3L Value Set for Belgium pp. 169-180

Sarah Dewilde, Bram Roudijk, Nafthali H. Tollenaar and Juan M. Ramos-Goñi

In a Child’s Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives pp. 181-192

Stefan A. Lipman, Brigitte A. B. Essers, Aureliano P. Finch, Ayesha Sajjad, Peep F. M. Stalmeier and Bram Roudijk

Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review pp. 183-201

Thitima Kongnakorn, Grammati Sarri, Andreas Freitag, Kinga Marczell, Paulina Kazmierska, Elizabeth Masters, Vivek Pawar and Xinke Zhang

A Value Set for the EQ-5D-Y-3L in the Netherlands pp. 193-203

Bram Roudijk, Ayesha Sajjad, Brigitte Essers, Stefan Lipman, Peep Stalmeier and Aureliano Paolo Finch

The Utility of a Rapid Review Evaluation Process to a National HTA Agency pp. 203-214

Áine Varley, Lesley Tilson, Emer Fogarty, Laura McCullagh and Michael Barry

Value Set for the EQ-5D-Y-3L in Hungary pp. 205-215

Fanni Rencz, Gábor Ruzsa, Alex Bató, Zhihao Yang, Aureliano Paolo Finch and Valentin Brodszky

The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions pp. 215-223

Yan Meng, Philip M. Clarke and Ilias Goranitis

EQ-5D-Y Value Set for Germany pp. 217-229

Simone Kreimeier, David Mott, Kristina Ludwig and Wolfgang Greiner

Is an Orphan Drug’s Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness? pp. 225-232

James D. Chambers, Nikoletta M. Margaretos, Daniel E. Enright, Rosa Wang and Xin Ye

Correction to: EQ-5D-Y Value Set for Germany pp. 231-231

Simone Kreimeier, David Mott, Kristina Ludwig and Wolfgang Greiner

The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS pp. 233-239

Megan Perry-Duxbury, James Lomas, Miqdad Asaria and Pieter Baal

Volume 40, issue 1, 2022

Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain pp. 3-5

Chris Skedgel

CHEERS to 30 Years of PharmacoEconomics pp. 5-6

Richard Milne and Christopher Carswell

In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era pp. 7-11

Werner Brouwer, Samare Huls, Ayesha Sajjad, Tim Kanters, Leona Hakkaart- van Roijen and Job Exel

Importance of Patient Involvement in the Value Assessment Process: On the Way Towards Personalised Treatments pp. 7-10

Nicole Gusset

Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management pp. 11-38

Noman Paracha, Pollyanna Hudson, Stephen Mitchell and C. Simone Sutherland

The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe pp. 13-29

Natalie Bohm, Sarah Bermingham, Frank Grimsey Jones, Daniela C. Gonçalves-Bradley, Alex Diamantopoulos, Jessica R. Burton and Hamish Laing

Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates pp. 31-43

Laura C. Edney, James Lomas, Jonathan Karnon, Laura Vallejo-Torres, Niek Stadhouders, Jonathan Siverskog, Mike Paulden, Ijeoma P. Edoka and Jessica Ochalek

Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers pp. 39-67

C. Simone Sutherland, Pollyanna Hudson, Stephen Mitchell and Noman Paracha

Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review pp. 45-64

Thomas Ward, Ruben E. Mujica-Mota, Anne E. Spencer and Antonieta Medina-Lara

A General Public Study on Preferences and Welfare Impacts of Antimicrobial Resistance in the United Kingdom pp. 65-76

Maria Veronica Dorgali, Alberto Longo, Caroline Vass, Gemma Shields, Roger Harrison, Riccardo Scarpa and Marco Boeri

Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA) pp. 69-89

Noman Paracha, Pollyanna Hudson, Stephen Mitchell and C. Simone Sutherland

Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic pp. 77-90

Samare P. I. Huls, Ayesha Sajjad, Tim A. Kanters, Leona Hakkaart- van Roijen, Werner Brouwer and Job Exel

Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom pp. 91-102

Siu Hing Lo, Ksenija Gorni, C. Simone Sutherland, Yasmina Martí, Andrew Lloyd and Noman Paracha

The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis pp. 91-108

Laurenske A. Visser, Marc Folcher, Claudia Delgado Simao, Biotza Gutierrez Arechederra, Encarna Escudero, Carin A. Uyl- de Groot and William Ken Redekop

Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries pp. 103-115

Siu Hing Lo, Claire Lawrence, Yasmina Martí, Andreia Café and Andrew J. Lloyd

Biased Survival Predictions When Appraising Health Technologies in Heterogeneous Populations pp. 109-120

Daniel Gallacher, Peter Kimani and Nigel Stallard

Correction to: Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain pp. 117-117

Chris Skedgel

Correction to: Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA) pp. 119-119

Noman Paracha, Pollyanna Hudson, Stephen Mitchell and C. Simone Sutherland

An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia pp. 121-131

Marjanne A. Piena, Natalie Houwing, Carla W. Kraan, Xiaofeng Wang, Heidi Waters, Ruth A. Duffy, Suresh Mallikaarjun and Craig Bennison

Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery pp. 133-135

Kevin M. Trentino, Hamish Mace and Axel Hofmann

Authors’ Response to “Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery” pp. 137-138

Bert Avau, Hans Van Remoortel, Emmy De Buck, Veerle Compernolle and Philippe Vandekerckhove

Correction to: A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population pp. 139-139

Emily McDool, Clara Mukuria and John Brazier